Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; and hemodiafilters for use as dialyzers in an hemodialysis treatment, as well as other disposables for use in the hemodiafiltration treatment process. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone201-343-5202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.69 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Nephros (OTCMKTS:NEPH) Frequently Asked Questions
What is Nephros' stock symbol?
Nephros trades on the OTCMKTS under the ticker symbol "NEPH."
How were Nephros' earnings last quarter?
Nephros, Inc. (OTCMKTS:NEPH) posted its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $1.61 million for the quarter. Nephros had a negative return on equity of 67.24% and a negative net margin of 59.82%. View Nephros' Earnings History.
When is Nephros' next earnings date?
Has Nephros been receiving favorable news coverage?
Press coverage about NEPH stock has trended positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nephros earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Nephros' key competitors?
Some companies that are related to Nephros include RenovaCare (RCAR), Sensus Healthcare (SRTS), Alphatec (ATEC), T2 Biosystems (TTOO), STRATA Skin Sciences (SSKN), iCAD (ICAD), Endologix (ELGX), Apollo Endosurgery (APEN), CAS Medical Systems (CASM), Titan Medical (TMDI), Invo Bioscience (IVOB), Motus GI (MOTS), Arch Therapeutics (ARTH), Spectral Medical (EDTXF) and Repro-Med Systems (REPR).
What other stocks do shareholders of Nephros own?
Who are Nephros' key executives?
Nephros' management team includes the folowing people:
- Mr. Daron G. Evans, Pres, CEO & Director (Age 45)
- Mr. Andrew Astor, CFO & COO (Age 62)
- Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.
How do I buy shares of Nephros?
Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nephros' stock price today?
One share of NEPH stock can currently be purchased for approximately $0.55.
How big of a company is Nephros?
Nephros has a market capitalization of $35.54 million and generates $5.69 million in revenue each year.
What is Nephros' official website?
How can I contact Nephros?
Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.
MarketBeat Community Rating for Nephros (OTCMKTS NEPH)
MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote "Outperform" if you believe NEPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
